Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stadler

Showing results (621-630 of 644) with videos related to

Pageof 65
Sort By:
JCO Precision Oncology|February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumMaria I Carlo, Veda N Giri, Channing J Paller, et al.
BJU International|November 14, 2013
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinomaGregory R Pond, Neeraj Agarwal, Joaquim Bellmunt, et al.
Clinical Pharmacology and Therapeutics|December 17, 2016
Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation ProgramR P McKillip, B A Borden, P Galecki, et al.
The Lancet. Oncology|March 20, 2025
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trialThomas Powles, Toni K Choueiri, Laurence Albiges, et al.
Clinical Genitourinary Cancer|August 8, 2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry ExperienceBrian A Costello, Nrupen A Bhavsar, Yousef Zakharia, et al.
European Urology|December 5, 2012
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsGuru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
Urologic Oncology|November 5, 2024
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meetingStephanie A Berg, Salvatore La Rosa, Tian Zhang, et al.
Cancer|March 25, 2021
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)Michael R Harrison, Brian A Costello, Nrupen A Bhavsar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell CarcinomaToni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012Maha Hussain, Stephanie Daignault-Newton, Przemyslaw W Twardowski, et al.
Pageof 65

Showing results (621-630 of 644) with videos related to

Sort By:
Pageof 65
JCO Precision Oncology|February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumMaria I Carlo, Veda N Giri, Channing J Paller, et al.
BJU International|November 14, 2013
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinomaGregory R Pond, Neeraj Agarwal, Joaquim Bellmunt, et al.
Clinical Pharmacology and Therapeutics|December 17, 2016
Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation ProgramR P McKillip, B A Borden, P Galecki, et al.
The Lancet. Oncology|March 20, 2025
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trialThomas Powles, Toni K Choueiri, Laurence Albiges, et al.
Clinical Genitourinary Cancer|August 8, 2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry ExperienceBrian A Costello, Nrupen A Bhavsar, Yousef Zakharia, et al.
European Urology|December 5, 2012
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsGuru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
Urologic Oncology|November 5, 2024
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meetingStephanie A Berg, Salvatore La Rosa, Tian Zhang, et al.
Cancer|March 25, 2021
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)Michael R Harrison, Brian A Costello, Nrupen A Bhavsar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell CarcinomaToni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012Maha Hussain, Stephanie Daignault-Newton, Przemyslaw W Twardowski, et al.
Pageof 65